# Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes

> **NCT06640283** · PHASE2 · RECRUITING · sponsor: **Instituto do Cancer do Estado de São Paulo** · enrollment: 150 (estimated)

## Conditions studied

- HPV-Related Carcinoma
- Uterine Cervical Cancer
- Anal Canal Cancer
- HPV-Related Anal Squamous Cell Carcinoma
- HPV-Related Cervical Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** ctDNA test
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06640283
- **Lead sponsor:** Instituto do Cancer do Estado de São Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-14
- **Primary completion:** 2026-12
- **Final completion:** 2027-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06640283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06640283, "Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT06640283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*